Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03187301 · ClinicalTrials.gov registry record · Phase 2
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT03187301 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 48 participants.
The verdict
NCT03187301, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
A cardiac safety study of an investigational drug to see how it affects the heart in people with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG APL-130277
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2017-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03187301
The ClinicalTrials.gov registry entry for NCT03187301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03187301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03187301 about?
NCT03187301 is a clinical study titled "A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes". A cardiac safety study of an investigational drug to see how it affects the heart in people with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
What is the current status of trial NCT03187301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2017-08-03. Estimated completion is 2017-12-21.
What interventions are being tested in trial NCT03187301?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), APL-130277 (DRUG).
Who is sponsoring clinical trial NCT03187301?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.